Semaglutide Dose Escalation — Week 8, now at 1.0mg

Following the STEP trial escalation schedule. Currently at the 1.0mg weekly dose level. The GI adaptation pattern described in the clinical trial data matches expectations — initial nausea typically subsides within 3-5 days of each dose increase.

Appetite suppression mechanisms via GLP-1R activation in the hypothalamus and brainstem appear to be dose-proportional based on the published PK/PD data.

Planning to hold at 1.0mg for an additional 4 weeks before considering further escalation.